Sberbank and R-Pharm Group announced the completion of their joint investment in SBER EAPTEKA.
Sberbank and R-Pharm Group will each have 45% of the company's shares, while Anton Buzdalin, the founder and CEO of SBER EAPTEKA, will retain a 10% stake. Sber's investment in the transaction (RUB 5.7 billion) will be used for corporate development (cash-in) aimed at improving the quality of service and expansion into Russian regions, which SBER EAPTEKA started in 2020. In 2021, the pharmacy business is expected to be launched in 76 more cities of Russia, with the online drug delivery service to be available to residents of many of them for the first time ever.
Since 2020, SBER EAPTEKA has been developing a system of pharmacy hubs intended for online sales. Pharmacy hubs reduce the load on the central warehouse and serve the surroundings to ensure express delivery within an hour.
Please note that this press release is based on materials provided by the company. AK&M Information Agency shall not be held liable for its contents, nor for the legal and other consequences of its publication.
